期刊文献+

新疆地区96例维族恶性黑素瘤临床特征及预后分析 被引量:5

Clinical and prognostic analysis of 96 patients with malignant melanoma in Xinjiang Region
下载PDF
导出
摘要 分析新疆地区维族恶性黑素瘤(MM)的临床及影响预后的因素。96例维族MM患者平均发病年龄为55.1±14.3岁,男女比为1.3:1,肢端为最常见的发病部位;淋巴结为最常见的转移部位,32例患者发生淋巴结转移;46例(47.9%)患者伴有原发病灶溃疡。存活时间中位数为38个月,5年生存率为37%。年龄、发病部位、是否溃疡、Clark分级、AJCC分期、BRAF基因突变与预后相关(P<0.05),而性别、是否淋巴结转移与预后不相关(P>0.05)。 The clinical data of 96 patients (54 males, 42 females) with malignant melanoma in Xinjiang Region were analyzed. The average age of the patients at onset was 55.1 ± 14.3 years. The most frequent loca- tion of the lesion was acra. Lymph node was the most frequent metastatic site which was seen in 32 patients. The lesion was ulcerated in 46 patients. The median survival time was 38.0 months. The 5-year survival rate was 37%. Statistical analysis showed that the prognosis of MM was correlated with age, site, ulcer, postopera- tive tumor margin, AJCC staging, Clark classification, treatment method and BRAF mutation (P〈0.05) and was uncorrelated with gender and lymph node metastasis (P〉0.05).
出处 《中国麻风皮肤病杂志》 2015年第5期259-261,264,共4页 China Journal of Leprosy and Skin Diseases
基金 乌鲁木齐市科技局基金项目(编号:G131310001)
关键词 恶性黑素瘤 临床 预后 malignant melanoma clinical prognosis
  • 相关文献

参考文献5

二级参考文献65

  • 1马水清,白春梅,于晓红,安云婷,郎景和.原发性子宫颈恶性黑色素瘤四例临床分析[J].中华妇产科杂志,2005,40(3):183-185. 被引量:8
  • 2刘丽影,李晓光,洪婉君,姚志惠,于国瑞,吴爱如,林冬梅.原发阴道恶性黑色素瘤22例[J].中华肿瘤杂志,1996,18(5):385-387. 被引量:3
  • 3安菊生,吴令英,李宁,李斌,俞高志,刘丽影.生殖系统原发性恶性黑色素瘤42例临床分析[J].中华妇产科杂志,2007,42(5):320-324. 被引量:13
  • 4Leiter U, Buettner PG, Eigentler TK, et al. Prognostic factors of thin cutaneous melanoma: An analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol, 2004, 22( 18 ): 3660-3667.
  • 5Scott RF, Kenneth MB, Gilda G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol, 2005, 23(28): 7168-7177.
  • 6Marko BL, Inger R, Anders A ,et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol, 2004, 22(21 ): 4369-4375.
  • 7Milton GW, Shaw HM. Rare variants of malignant melanoma. World J Surg, 1992, 16(2): 173-178.
  • 8Lawson DH. Update on the systemic treatment of malignant melanoma. Semin Oncol, 2004, 31(2 Suppl 4): 33-37.
  • 9Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol, 2000, 18 ( 12): 2444-2458.
  • 10Koh HK, Geller AC, Miller DR, et al. Prevention and early detection strategies for melanoma and skin cancer: current status. Arch Dermatol, 1996, 132(4): 436-443.

共引文献49

同被引文献24

  • 1王景权,陈茜,王亚萍,宣小辉,张壤之.75例皮肤肿瘤临床分析[J].皮肤病与性病,2004,26(2):6-7. 被引量:5
  • 2涂亚庭,林云,陶娟,张丽霞,吴艳.皮肤恶性黑素瘤凋亡相关基因Survivin Bax表达及其与端粒酶的关系[J].中国皮肤性病学杂志,2005,19(6):325-328. 被引量:3
  • 3Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma [ J ]. Science, 2013, 339 ( 6122 ) : 959-961. DOI : 10.1126/science. 1230062.
  • 4Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma [ J ]. Science, 2013, 339 ( 6122 ) : 957-959. DOI : 10.1126/science. 1229259.
  • 5de Jesus BB, Blasco MA. Telomerase at the intersection of cancer and aging [ J ]. Trends Genet, 2013, 29 ( 9 ) : 513-520. DOI : 10.1016/j. tig.2013.06.007.
  • 6Katunari C, Jurisi C, Hadzisejdi C, et al. Real-time expression of hTERT in primary melanoma biopsies [ J ]. Coll Antropol, 2010, 34 ( 4 ) : 1401-1404.
  • 7Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma [ J ]. Clin Cancer Res, 2011,17 ( 7 ) : 1684-1691. DOI: 10.1158/1078-0432.CCR-10-2346.
  • 8Kang XJ, Shi XH, Chen WJ, et al. Analysis of KIT mutations and c-KIT expression in Chinese Uygur and Han patients with melanoma [ J ]. Clin Exp Dermatol, 2016, 41 ( 1 ) :81-87. DOI: 10.1111/ted. 12659.
  • 9Mihajlovie M, Vlajkovic S, Jovanovic P, et al. Primary mueosal melanomas:a comprehensive review [J]. Int J Clin Exp Pathol, 2012, 5 ( 8 ) : 739-753.
  • 10Bertorelle R, Briarava M, Rampazzo E, et al. Telomerase is an independent prognostic marker of overall smwival in patients with colol~ctal cancer [ J ]. Br J Cancer, 2013, 108 ( 2 ) : 278-284. DOI : 10.1038/bjc.2012.602.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部